Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 7, 2014, Pages 1249-1250

  Cristóbal, Ion ^a   Manso, Rebeca ^a   Rincón, Raúl ^a   Madoz Gúrpide, Juan ^a   Caramés, Cristina ^a   Rojo, Federico ^a   García Foncillas, Jesús ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; FINGOLIMOD; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; TEMSIROLIMUS;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER CELL LINE; COLORECTAL CANCER; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; LETTER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; SENSITIZATION; UBIQUITINATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOANTIGENS; COLONIC NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MEMBRANE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84904113094     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1707-2     Document Type: Letter

References (6)

1. Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A, Martinez-Useros J, Rodriguez M, Zazo S, Martinez-Aguilera O, Madoz-Gurpide J, Rojo F,Garcia-Foncillas J (2014) PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 13(4):938-947
2. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, ARCC Global Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271-2281 (Pubitemid 46849157)
3. Junttila MR, Westermarck J (2008) Mechanisms of MYC stabilization in human malignancies. Cell Cycle 7(5):592-596 (Pubitemid 351498996)
4. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J (2007) CIP2A inhibits PP2A in human malignancies. Cell 130(1):51-62 (Pubitemid 47039258)
5. Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R (2013) Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res 19(1):138-147. doi:10.1158/1078-0432. CCR-12-1050
6. Wang HW, Yang SH, Huang GD, Lin JK, Chen WS, Jiang JK, Lan YT, Lin CC, Hwang WL, Tzeng CH, Li AF, Yen CC, Teng HW (2014) Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism. J Cancer Res Clin Oncol 140(4):561-571. doi:10.1007/s00432-014-1596-4